Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Hypersensitivity 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER × Cetirizine × Clear all
NCT06039137 2024-09-25

H1-Switch

Erasmus Medical Center

Completed
395 enrolled

Hypersensitivity, Neoplasms

NCT04237090 2020-10-12

PREMED-F1

Ciusss de L'Est de l'Île de Montréal

Phase 3 Completed
27 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡